What is Orthofix Med Inc's earnings per share (EPS)?

Orthofix Med Inc (OFIX) reported diluted earnings per share of $-2.33 for fiscal year 2025. This represents a 29.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Orthofix Med Inc Financials

OFIX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Orthofix Med Inc (OFIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 34/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Orthofix Med Inc has an operating margin of -9.9%, meaning the company retains $-10 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -10.6% the prior year.

Growth

Orthofix Med Inc's revenue grew a modest 2.9% year-over-year to $822.3M. This slow but positive growth earns a score of 38/100.

Leverage

Orthofix Med Inc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Orthofix Med Inc's current ratio of 2.45 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Orthofix Med Inc generated $33.3M in operating cash flow, capex of $34.6M consumed most of it, leaving -$1.3M in free cash flow. This results in a low score of 25/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Orthofix Med Inc generates a -20.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -25.0% the prior year.

Piotroski F-Score Neutral

5/9

Orthofix Med Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

-0.36x

For every $1 of reported earnings, Orthofix Med Inc generates $-0.36 in operating cash flow ($33.3M OCF vs -$92.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-4.7x

Orthofix Med Inc earns $-4.7 in operating income for every $1 of interest expense (-$81.4M vs $17.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$822.3M

YoY+2.9%

5Y CAGR+15.1%

10Y CAGR+7.6%

Orthofix Med Inc generated $822.3M in revenue in fiscal year 2025. This represents an increase of 2.9% from the prior year.

EBITDA

-$4.1M

YoY+83.3%

Orthofix Med Inc's EBITDA was -$4.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 83.3% from the prior year.

Net Income

-$92.2M

YoY+26.8%

Orthofix Med Inc reported -$92.2M in net income in fiscal year 2025. This represents an increase of 26.8% from the prior year.

EPS (Diluted)

$-2.33

YoY+29.4%

Orthofix Med Inc earned $-2.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.3M

YoY+85.9%

Orthofix Med Inc generated -$1.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 85.9% from the prior year.

Cash & Debt

$82.0M

YoY-1.5%

5Y CAGR-3.2%

10Y CAGR+2.6%

Orthofix Med Inc held $82.0M in cash against $157.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

40M

YoY+3.5%

5Y CAGR+15.4%

10Y CAGR+7.9%

Orthofix Med Inc had 40M shares outstanding in fiscal year 2025. This represents an increase of 3.5% from the prior year.

Margins & Returns

Gross Margin

68.8%

YoY+0.6pp

5Y CAGR-6.1pp

10Y CAGR-9.4pp

Orthofix Med Inc's gross margin was 68.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

-9.9%

YoY+0.7pp

5Y CAGR-8.4pp

10Y CAGR-12.2pp

Orthofix Med Inc's operating margin was -9.9% in fiscal year 2025, reflecting core business profitability. This is up 0.7 percentage points from the prior year.

Net Margin

-11.2%

YoY+4.5pp

5Y CAGR-11.8pp

10Y CAGR-10.5pp

Orthofix Med Inc's net profit margin was -11.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.5 percentage points from the prior year.

Return on Equity

-20.5%

YoY+4.6pp

5Y CAGR-21.2pp

10Y CAGR-19.5pp

Orthofix Med Inc's ROE was -20.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$65.8M

YoY-10.6%

5Y CAGR+11.0%

10Y CAGR+9.6%

Orthofix Med Inc invested $65.8M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$34.6M

YoY-0.7%

5Y CAGR+17.5%

10Y CAGR+2.4%

Orthofix Med Inc invested $34.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.7% from the prior year.

OFIX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$822.3M+2.9%	$799.5M+7.1%	$746.6M+62.1%	$460.7M-0.8%	$464.5M+14.2%	$406.6M
Cost of Revenue	$256.3M+1.1%	$253.6M-2.6%	$260.4M+110.7%	$123.5M+7.5%	$114.9M+12.8%	$101.9M
Gross Profit	$566.0M+3.7%	$545.9M+12.3%	$486.3M+44.2%	$337.2M-3.5%	$349.6M+14.7%	$304.7M
R&D Expenses	$65.8M-10.6%	$73.6M-8.2%	$80.2M+63.5%	$49.1M-1.1%	$49.6M+27.1%	$39.1M
SG&A Expenses	$554.3M+4.1%	$532.5M+0.4%	$530.4M+71.8%	$308.8M+345.2%	$69.4M+2.1%	$67.9M
Operating Income	-$81.4M+3.8%	-$84.6M+39.2%	-$139.1M-948.5%	-$13.3M-59.6%	-$8.3M-32.7%	-$6.3M
Interest Expense	-$17.5M+41.0%	-$29.6M-243.3%	-$8.6M-570.1%	-$1.3M+29.9%	-$1.8M+26.0%	-$2.5M
Income Tax	$1.4M-34.9%	$2.1M-21.9%	$2.7M+32.9%	$2.0M-91.8%	$24.9M+962.5%	-$2.9M
Net Income	-$92.2M+26.8%	-$126.0M+16.8%	-$151.4M-666.6%	-$19.7M+48.5%	-$38.4M-1624.8%	$2.5M
EPS (Diluted)	$-2.33+29.4%	$-3.30+19.9%	$-4.12-320.4%	$-0.98+49.7%	$-1.95-1600.0%	$0.13

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$219.9M+6.9%	$205.6M+1.2%	$203.1M+4.9%	$193.6M-10.2%	$215.7M+9.7%	$196.6M-1.0%	$198.6M+5.3%	$188.6M
Cost of Revenue	$63.6M+11.3%	$57.1M-10.2%	$63.6M-11.7%	$72.0M+7.8%	$66.8M+8.6%	$61.6M-3.6%	$63.9M+4.1%	$61.4M
Gross Profit	$156.3M+5.3%	$148.5M+6.4%	$139.5M+14.7%	$121.6M-18.3%	$148.8M+10.2%	$135.1M+0.2%	$134.7M+5.9%	$127.2M
R&D Expenses	$15.4M+4.1%	$14.8M-7.3%	$15.9M-19.4%	$19.8M+5.1%	$18.8M+8.8%	$17.3M-4.2%	$18.0M-7.4%	$19.5M
SG&A Expenses	$136.8M-7.7%	$148.1M+8.5%	$136.5M+2.6%	$133.0M-2.6%	$136.5M+4.9%	$130.1M-3.0%	$134.2M+1.9%	$131.7M
Operating Income	$494K+102.9%	-$17.0M-6.5%	-$16.0M+67.3%	-$48.9M-325.8%	-$11.5M+39.3%	-$18.9M+24.1%	-$24.9M+15.1%	-$29.3M
Interest Expense	-$4.4M+7.0%	-$4.7M-18.5%	-$4.0M+12.3%	-$4.5M+69.8%	-$14.9M-186.4%	-$5.2M-5.4%	-$4.9M-8.4%	-$4.6M
Income Tax	$30K-94.4%	$533K+475.4%	-$142K-114.8%	$961K+270.4%	-$564K-175.1%	$751K-30.7%	$1.1M+27.4%	$851K
Net Income	-$2.2M+90.3%	-$22.8M-61.9%	-$14.1M+73.5%	-$53.1M-82.2%	-$29.1M-6.4%	-$27.4M+18.1%	-$33.4M+7.2%	-$36.0M
EPS (Diluted)	N/A	$-0.57-58.3%	$-0.36+73.3%	$-1.35	N/A	$-0.71+19.3%	$-0.88+7.4%	$-0.95

OFIX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$850.6M-4.8%	$893.3M-3.5%	$925.3M+101.8%	$458.6M-3.8%	$476.6M-9.4%	$525.9M
Current Assets	$416.8M-3.8%	$433.3M+3.1%	$420.4M+64.2%	$256.0M-5.0%	$269.5M-0.3%	$270.4M
Cash & Equivalents	$82.0M-1.5%	$83.2M+151.4%	$33.1M-34.7%	$50.7M-42.3%	$87.8M-8.8%	$96.3M
Inventory	$172.3M-9.0%	$189.5M-14.7%	$222.2M+121.8%	$100.2M+20.7%	$83.0M-2.0%	$84.6M
Accounts Receivable	$135.7M+0.8%	$134.7M+5.2%	$128.1M+54.6%	$82.9M+5.5%	$78.6M+8.5%	$72.4M
Goodwill	$194.9M0.0%	$194.9M0.0%	$194.9M+173.3%	$71.3M0.0%	$71.3M-15.1%	$84.0M
Total Liabilities	$400.6M+2.7%	$390.2M+19.5%	$326.6M+168.2%	$121.8M-12.8%	$139.7M-17.3%	$169.0M
Current Liabilities	$170.5M+1.1%	$168.6M+2.1%	$165.2M+97.6%	$83.6M-21.0%	$105.8M+1.9%	$103.9M
Long-Term Debt	$157.4M+0.2%	$157.0M+68.6%	$93.1M	N/A	N/A	N/A
Total Equity	$450.0M-10.6%	$503.1M-16.0%	$598.7M+77.7%	$336.9M0.0%	$336.9M-5.6%	$356.9M
Retained Earnings	-$368.3M-33.4%	-$276.1M-83.9%	-$150.1M-12101.9%	$1.3M-94.0%	$21.0M-64.6%	$59.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$850.6M+2.2%	$832.6M-0.5%	$837.2M+1.7%	$823.1M-7.9%	$893.3M+2.9%	$867.9M-1.6%	$882.0M-2.7%	$906.0M
Current Assets	$416.8M+5.8%	$394.2M-0.4%	$395.8M+1.4%	$390.3M-9.9%	$433.3M+12.2%	$386.2M0.0%	$386.1M-3.2%	$399.0M
Cash & Equivalents	$82.0M+30.5%	$62.9M-4.2%	$65.6M+13.2%	$58.0M-30.4%	$83.2M+177.0%	$30.1M+14.0%	$26.4M-2.2%	$27.0M
Inventory	$172.3M-1.0%	$174.0M+0.6%	$173.0M-0.9%	$174.5M-7.9%	$189.5M-7.9%	$205.8M-2.0%	$210.0M-4.1%	$219.1M
Accounts Receivable	$135.7M+3.8%	$130.8M+1.0%	$129.6M-1.8%	$131.9M-2.1%	$134.7M+7.9%	$124.8M-0.4%	$125.4M-0.2%	$125.6M
Goodwill	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M
Total Liabilities	$400.6M+2.7%	$390.1M+3.0%	$378.8M+3.8%	$364.9M-6.5%	$390.2M+14.1%	$341.9M+1.8%	$336.0M+0.1%	$335.7M
Current Liabilities	$170.5M+6.7%	$159.8M+7.7%	$148.4M+3.0%	$144.1M-14.5%	$168.6M+4.2%	$161.9M+3.8%	$156.0M+3.5%	$150.6M
Long-Term Debt	$157.4M+0.1%	$157.2M+0.1%	$157.0M+0.1%	$156.9M-0.1%	$157.0M+39.9%	$112.2M-1.0%	$113.3M-1.5%	$115.1M
Total Equity	$450.0M+1.7%	$442.5M-3.5%	$458.3M0.0%	$458.3M-8.9%	$503.1M-4.3%	$525.9M-3.7%	$546.0M-4.3%	$570.3M
Retained Earnings	-$368.3M-0.6%	-$366.1M-6.6%	-$343.3M-4.3%	-$329.2M-19.2%	-$276.1M-11.8%	-$247.0M-12.5%	-$219.6M-18.0%	-$186.2M

OFIX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$33.3M+29.3%	$25.8M+156.4%	-$45.8M-296.5%	-$11.5M-162.5%	$18.5M-75.1%	$74.3M
Capital Expenditures	$34.6M-0.7%	$34.9M-42.1%	$60.3M+182.0%	$21.4M+20.1%	$17.8M+14.9%	$15.5M
Free Cash Flow	-$1.3M+85.9%	-$9.1M+91.4%	-$106.0M-222.2%	-$32.9M-4868.4%	$690K-98.8%	$58.8M
Investing Cash Flow	-$34.6M-25.4%	-$27.6M+16.8%	-$33.1M-35.0%	-$24.5M-6.6%	-$23.0M+56.0%	-$52.3M
Financing Cash Flow	-$786K-101.6%	$50.7M-22.4%	$65.3M+83846.2%	-$78K+97.8%	-$3.6M-211.6%	$3.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$27.7M+123.3%	$12.4M+6.6%	$11.6M+163.3%	-$18.4M-177.5%	$23.7M+103.3%	$11.7M+29.9%	$9.0M+148.3%	-$18.6M
Capital Expenditures	$10.9M+9.8%	$9.9M+39.3%	$7.1M+5.5%	$6.7M-21.0%	$8.5M+46.8%	$5.8M-41.8%	$10.0M-5.2%	$10.5M
Free Cash Flow	$16.8M+573.3%	$2.5M-44.9%	$4.5M+118.0%	-$25.1M-265.3%	$15.2M+159.4%	$5.9M+682.4%	-$1.0M+96.5%	-$29.1M
Investing Cash Flow	-$10.9M-9.9%	-$9.9M-39.4%	-$7.1M-5.4%	-$6.7M-493.5%	-$1.1M+80.6%	-$5.9M+39.7%	-$9.7M+10.6%	-$10.9M
Financing Cash Flow	$2.4M+146.1%	-$5.2M-295.2%	$2.6M+505.5%	-$651K-102.1%	$31.5M+1382.0%	-$2.5M-1191.6%	$225K-99.0%	$21.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OFIX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	68.8%+0.6pp	68.3%+3.1pp	65.1%-8.1pp	73.2%-2.1pp	75.3%+0.3pp	74.9%
Operating Margin	-9.9%+0.7pp	-10.6%+8.0pp	-18.6%-15.8pp	-2.9%-1.1pp	-1.8%-0.2pp	-1.5%
Net Margin	-11.2%+4.5pp	-15.8%+4.5pp	-20.3%-16.0pp	-4.3%+4.0pp	-8.3%-8.9pp	0.6%
Return on Equity	-20.5%+4.6pp	-25.0%+0.3pp	-25.3%-19.4pp	-5.9%+5.5pp	-11.4%-12.1pp	0.7%
Return on Assets	-10.8%+3.3pp	-14.1%+2.3pp	-16.4%-12.0pp	-4.3%+3.7pp	-8.1%-8.5pp	0.5%
Current Ratio	2.45-0.1	2.57+0.0	2.54-0.5	3.06+0.5	2.55-0.1	2.60
Debt-to-Equity	0.35+0.0	0.31+0.2	0.16-0.2	0.36-0.1	0.41-0.1	0.47
FCF Margin	-0.2%+1.0pp	-1.1%+13.1pp	-14.2%-7.1pp	-7.1%-7.3pp	0.1%-14.3pp	14.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	71.1%-1.1pp	72.2%+3.5pp	68.7%+5.9pp	62.8%-6.2pp	69.0%+0.3pp	68.7%+0.8pp	67.8%+0.4pp	67.5%
Operating Margin	0.2%+8.5pp	-8.3%-0.4pp	-7.9%+17.4pp	-25.2%-19.9pp	-5.3%+4.3pp	-9.6%+2.9pp	-12.5%+3.0pp	-15.6%
Net Margin	-1.0%+10.1pp	-11.1%-4.2pp	-6.9%+20.5pp	-27.4%-13.9pp	-13.5%+0.4pp	-13.9%+2.9pp	-16.8%+2.3pp	-19.1%
Return on Equity	-0.5%+4.7pp	-5.1%-2.1pp	-3.1%+8.5pp	-11.6%-5.8pp	-5.8%-0.6pp	-5.2%+0.9pp	-6.1%+0.2pp	-6.3%
Return on Assets	-0.3%+2.5pp	-2.7%-1.1pp	-1.7%+4.8pp	-6.5%-3.2pp	-3.3%-0.1pp	-3.2%+0.6pp	-3.8%+0.2pp	-4.0%
Current Ratio	2.45-0.0	2.47-0.2	2.67-0.0	2.71+0.1	2.57+0.2	2.39-0.1	2.48-0.2	2.65
Debt-to-Equity	0.350.0	0.36+0.0	0.340.0	0.34+0.0	0.31+0.1	0.210.0	0.210.0	0.20
FCF Margin	7.6%+6.4pp	1.2%-1.0pp	2.2%+15.2pp	-13.0%-20.0pp	7.0%+4.1pp	3.0%+3.5pp	-0.5%+14.9pp	-15.4%

Similar Companies

$651.6M

$615.1M

$557.8M

$535.7M

$401.2M

Frequently Asked Questions

What is Orthofix Med Inc's annual revenue?

Orthofix Med Inc (OFIX) reported $822.3M in total revenue for fiscal year 2025. This represents a 2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Orthofix Med Inc's revenue growing?

Orthofix Med Inc (OFIX) revenue grew by 2.9% year-over-year, from $799.5M to $822.3M in fiscal year 2025.

Is Orthofix Med Inc profitable?

No, Orthofix Med Inc (OFIX) reported a net income of -$92.2M in fiscal year 2025, with a net profit margin of -11.2%.

What is Orthofix Med Inc's EBITDA?

Orthofix Med Inc (OFIX) had EBITDA of -$4.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Orthofix Med Inc have?

As of fiscal year 2025, Orthofix Med Inc (OFIX) had $82.0M in cash and equivalents against $157.4M in long-term debt.

What is Orthofix Med Inc's gross margin?

Orthofix Med Inc (OFIX) had a gross margin of 68.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Orthofix Med Inc's operating margin?

Orthofix Med Inc (OFIX) had an operating margin of -9.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Orthofix Med Inc's net profit margin?

Orthofix Med Inc (OFIX) had a net profit margin of -11.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Orthofix Med Inc's return on equity (ROE)?

Orthofix Med Inc (OFIX) has a return on equity of -20.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Orthofix Med Inc's free cash flow?

Orthofix Med Inc (OFIX) generated -$1.3M in free cash flow during fiscal year 2025. This represents a 85.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Orthofix Med Inc's operating cash flow?

Orthofix Med Inc (OFIX) generated $33.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Orthofix Med Inc's total assets?

Orthofix Med Inc (OFIX) had $850.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Orthofix Med Inc's capital expenditures?

Orthofix Med Inc (OFIX) invested $34.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Orthofix Med Inc spend on research and development?

Orthofix Med Inc (OFIX) invested $65.8M in research and development during fiscal year 2025.

How many shares does Orthofix Med Inc have outstanding?

Orthofix Med Inc (OFIX) had 40M shares outstanding as of fiscal year 2025.

What is Orthofix Med Inc's current ratio?

Orthofix Med Inc (OFIX) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.

What is Orthofix Med Inc's debt-to-equity ratio?

Orthofix Med Inc (OFIX) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Orthofix Med Inc's return on assets (ROA)?

Orthofix Med Inc (OFIX) had a return on assets of -10.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Orthofix Med Inc's Piotroski F-Score?

Orthofix Med Inc (OFIX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Orthofix Med Inc's earnings high quality?

Orthofix Med Inc (OFIX) has an earnings quality ratio of -0.36x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Orthofix Med Inc cover its interest payments?

Orthofix Med Inc (OFIX) has an interest coverage ratio of -4.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Orthofix Med Inc?

Orthofix Med Inc (OFIX) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.